Top 10 Vaccines in 2013

  #10 – Pneumovax Pneumococcal infection 2013 – $653 million 2012 – $580 million Marketed by Merck and Sanofi Pasteur MSD #9 – RotaTeq Rotaviral gastroenteritis 2013 – $691 million 2012 – $648 million Marketed by Merck and Sanofi Pasteur MSD #8 – Zostavax Herpes Zoster (Shingles) 2013 – $826 million 2012 – $ N/A Marketed by Merck and Sanofi Pasteur MSD #7 – Hepatitis vaccine franchise Hepatitis A, Hepatitis B 2013 – $984 million 2012 …